Recent biopharma financing and royalty deals highlight ongoing financial dynamism within the sector. Royalty Pharma acquired BeOne’s share of Amgen’s lung cancer drug royalties for $885 million upfront, capitalizing on high-demand oncology therapies. Additionally, novel immigrants and biotech startups secured significant seed funding to bolster RNA therapeutics and delivery platforms. These transactions reflect intensified financial strategies to support late-stage development and innovation.